<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652258</url>
  </required_header>
  <id_info>
    <org_study_id>NovartisIIT/ 2020-01929</org_study_id>
    <nct_id>NCT04652258</nct_id>
  </id_info>
  <brief_title>Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy</brief_title>
  <acronym>Nov IIT- Pyrex</acronym>
  <official_title>A Phase II, Open Label, Single Arm, Single Center Study to Evaluate Pyrexia Management (With or Without Any Other Cytokine Release Symptoms) Using Tocilizumab, an Humanized Monoclonal Antibody Against the Interleukin - 6 Receptor in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study examines the development of fever after administration of Actemra (tocilizumab) in&#xD;
      patients who have fever and other cytokine release symptoms (headache, nausea, palpitations,&#xD;
      low blood pressure) due to cancer therapy (Tafinlar (dabrafenib) / Mekinist (trametinib) +/-&#xD;
      immunotherapy) . The goal of the study is to better understand the side effects and to find&#xD;
      an effective therapy against them.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pyrexia management</measure>
    <time_frame>1 hour to up to 72 hours.</time_frame>
    <description>The primary outcome represents the proportion of patients that reduce to at least &lt;38°C after tocilizumab infusion in BRAF+ melanoma patients under treatment with dabrafenib/trametinib +/- immunotherapy - pyrexia status will be assessed at screening visit and on every other defined visit until remission, by assessing body temperature.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pyrexia</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients will be administered Tocilizmab (Actemra) at the following dosage :&#xD;
First dose: 8mg/kg, max. 800mg iv. during 60min&#xD;
If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actemra</intervention_name>
    <description>Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed Consent as documented by signature&#xD;
&#xD;
          2. Subjects (males and females) age ≥ 18 years&#xD;
&#xD;
          3. ECOG &lt; 3&#xD;
&#xD;
          4. Subjects with pyrexia grade 1*- 4 and elevated CRP with persistent fever after one day&#xD;
             of antipyretic therapy with or without at least one other additional symptom of&#xD;
             cytokine release syndrome such as nausea, headache, tachycardia, hypotension,&#xD;
             maculopapular rash, shortness of breath, transaminitis, renal failure, dehydration&#xD;
&#xD;
          5. Elevated CRP serum levels further than normal baseline levels (&gt; 3.0 mg/L)&#xD;
&#xD;
          6. Subjects with resected, non-resectable, adjuvant or metastatic BRAF+ melanoma treated&#xD;
             with :&#xD;
&#xD;
               -  BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib)&#xD;
&#xD;
               -  BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib)&#xD;
                  preceded by therapy with anti-PD-1/PD-L1 and/or anti CTLA-4 inhibitor&#xD;
&#xD;
               -  BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib) plus&#xD;
                  anti-PD- 1/PD-L1 inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Zurich, Clinic of Dermatology</name>
      <address>
        <city>Zürich</city>
        <zip>8058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Dummer, Prof.</last_name>
      <phone>+41442552507</phone>
      <email>reinhard.dummer@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

